PEDIATRIC ONCOLOGY GROUP

儿科肿瘤学小组(POG)是一个多学科、多领域的 合作增加知识的机构研究社区 改善儿童癌症和白血病的治疗，以及 青少年。蒙特利尔儿童医院/麦吉尔大学(MCH) 创始成员，要求为自己及其两个附属公司提供资金 东安大略省儿童医院(CHEO)和安大略省大学 舍布鲁克医疗中心(USMC)将继续全面参与 在接下来的5年中，联合国环境保护组的行政和科学活动 好几年了。我们预计每年总共招募70名患者接受治疗 儿童白血病、淋巴瘤、实体瘤和脑的治疗方案 肿瘤，继续强调新药物的I期和II期研究 以及至少13项议定书的协调或共同协调。我们 预计每年招募110名患者参加非治疗性研究 癌症病因学、流行病学、生物学、心理学影响和晚期 治疗的效果，特别强调药理学和 甲氨蝶呤治疗急性淋巴细胞白血病的分子药理学研究 (全部)。我们将遵守POG章程的所有要求，并 管理临床研究的道德行为的条例和 OPRR和IRB对受试者知情同意和保护的要求 避免研究风险。 除了预期患者收益自5年以来翻了一番外 之前，我们对POG研究的主要贡献将包括：确认 甲氨蝶呤多谷氨酸的蓄积程度 B祖细胞中的淋巴母细胞均与无事件生存相关 (EFS)及其代谢调控机制的表征 (怀特黑德)；通过新药促进新药开发 和药理学委员会领导层(怀特黑德和伯恩斯坦)和 方案协调(伯恩斯坦、巴鲁切尔)；立体定向简介 脑肿瘤的分次立体定向放射治疗 (弗里曼)；协调新诊断和新诊断的 复发的B-祖细胞ALL(Abish，Bernstein)；介绍新的 作为小组委员会的复发性淋巴系统疾病的药物和组合物 淋巴复发椅子(伯恩斯坦)；脑部化疗和手术 肿瘤(Baruchel、Ventureyra)；生物学研究，包括P53 基因突变和艾滋病毒相关淋巴瘤的治疗(Baruchel， 怀特黑德)。

The Pediatric Oncology Group (POG) is a multi-disciplinary, multi- institutional research community which collaborates to increase knowledge of and improve treatment for cancer and leukemia in children and adolescents. The Montreal Children's Hospital/McGill University (MCH), a founding member, requests funding for itself and its two affiliates, the Children's Hospital of Eastern Ontario (CHEO) and the University of Sherbrooke Medical Center (USMC) to continue to participate fully in administrative and scientific activities of the POG during the next 5 years. We expect to enroll a total of 70 patients a year on therapeutic protocols for childhood leukemias, lymphomas, solid tumors and brain tumors, with continued emphasis on Phase I and II studies of new agents and coordination or co-coordination of a minimum of 13 protocols. We expect to enroll 110 patients per year on non-therapeutic studies of cancer etiology, epidemiology, biology, psychologic impact and late effects of therapy with particular emphasis on the pharmacology and molecular pharmacology of methotrexate in acute lymphoblastic leukemia (ALL). We will comply with all requirements of the POG constitution, with MR regulations governing ethical conduct of clinical research and with OPRR and IRB requirements for informed consent and protection of subjects from research risks. In addition to an anticipated doubling of patient accruals since 5 years ago, our major contributions to POG research will include: confirmation that the extent of accumulation of methotrexate polyglutamates by lymphoblasts in B-progenitor cell ALL correlates with event-free survival (EFS) and characterization of the mechanisms regulating this metabolism (Whitehead); promotion of new agent drug development through New Agents and Pharmacology Committee leadership (Whitehead and Bernstein) and protocol coordination (Bernstein, Baruchel); introduction of stereotactic and fractionated stereotactic radiation therapy in brain tumors (Freeman); coordination of treatment protocols of newly-diagnosed and relapsed B-progenitor cell ALL (Abish, Bernstein); introduction of new agents and combinations in recurrent lymphoid disease as Sub-committee Chair, Lymphoid Relapse (Bernstein); chemotherapy and surgery of brain tumors (Baruchel, Ventureyra); and study of the biology, including p53 gene mutations, and treatment of HIV-related lymphomas (Baruchel, Whitehead).